History

Foundation of APREX and generation 1 & 2 of MEMS® hardware technology by John Urquhart.

First MEMS^® - based peer-reviewed publication in JAMA

Generation 3 of MEMS^® technology

First phase IV clinical study sponsored by Pfizer comparing anti-hypertensive treatmentforgiveness

Generation 4 of MEMS^® technology

First audit by a large pharma company (Ely Lilly)

Foundation of AARDEX Group in Switzerland and acquisition of APREX by Dr Jean-Michel Métry.

Generation 5 of MEMS^® technology

First ISO9001 compliance certification

Opening of the AARDEX Group research center in Belgium

First FDA filing of MEMS^® data from large scale Phase II/III Drug development program for HIV

Generation 6 of MEMS^® technology

Launch of medAmigo (currently known as MEMS^® Adherence Software)

Creation of the largest repository of dosing history data and the AARDEX Group knowledge center

First deployment of MEMS^®adherence hardware and MEMS^® adherence software in large scale Drug development of new, all oral, HCV therapies (multi-company, multi-study, multi-country, multi-site)

Acquisition of AARDEX Group by MWV

First large scale adherence-enhancing program based on MEMS^®adherence hardware and software in resource-limited setting sponsored by the Bill & Melinda Gates Foundation

MWV merger with Rocktenn to become Westrock

Generation 8 of the MEMS^® family of adherence hardware

MBO from WestRock by its CSO, Dr Bernard Vrijens.

HQ of AARDEX Group now operating from Belgium with subsidiary of AARDEX Group in Switzerland